Dogruel H, Balci MK. Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future. World J Diabetes 2019; 10(8): 446-453 [PMID: 31523380 DOI: 10.4239/wjd.v10.i8.446]
Corresponding Author of This Article
Mustafa Kemal, MD, Doctor, Department of Internal Medicine, Antalya Ataturk State Hospital, Anafartalar street, No. 100, Antalya 07070, Turkey. mkbalci@msn.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Aug 15, 2019; 10(8): 446-453 Published online Aug 15, 2019. doi: 10.4239/wjd.v10.i8.446
Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future
Hakan Dogruel, Mustafa Kemal Balci
Hakan Dogruel, Department of Internal Medicine, Antalya Ataturk State Hospital, Antalya 07040, Turkey
Mustafa Kemal Balci, Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Antalya 07070, Turkey
Author contributions: Dogruel H and Balci MK conceived of and designed the study; Dogruel H searched the literature and drafted the article; both authors revised the article and Balci MK gave final approval for the article.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mustafa Kemal, MD, Doctor, Department of Internal Medicine, Antalya Ataturk State Hospital, Anafartalar street, No. 100, Antalya 07070, Turkey. mkbalci@msn.com
Telephone: +90-505-4789010 Fax: +90-242-2496040
Received: March 22, 2019 Peer-review started: March 22, 2019 First decision: May 31, 2019 Revised: June 13, 2019 Accepted: July 27, 2019 Article in press: July 27, 2019 Published online: August 15, 2019 Processing time: 146 Days and 22.9 Hours
Abstract
Diabetes mellitus (DM) is a chronic metabolic disease characterized by hypergly-cemia. Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide prevalence of DM is rising dramatically over the last decades, from 30 million cases in 1985 to 382 million cases in 2013. It’s estimated that 451 million people had diabetes in 2017. As the pathophysiology was understood over the years, treatment options for diabetes increased. Incretin-based therapy is one of them. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) not only significantly lower glucose level with minimal risk of hypoglycemia but also, they have an important advantage in themanagement of cardiovascular risk and obesity. Thus, we will review here GLP-1 RAsrole in the treatment of diabetes.
Core tip: The prevalence of type 2 diabetes and its complications rising dramatically over the last years. It is well known that diabetes and its complications; especially cardiovascular complications lead to increased morbidity and mortality. Treatment options for diabetes have increased as the pathophysiology was understood. We discuss the incretin-based therapy, especially Glucagon-like peptide-1 receptor agonistsand the beneficial effects on comorbidities besides glucose lowering effect.
